Shots:

• GI Innovations to receive $17M upfront- $1.2B as development & commercialization milestones along with royalties on sales of therapy
• Yuhan to get global rights (Ex-Japan) to develop and commercialize GI-301 while collaborates with GI Innovations for the development of therapy
• As per collaboration- the companies will develop allergy treatment across all four major allergic diseases-allergic asthma- chronic urticaria- atopic dermatitis- and food allergy

Click here to read full press release/ article | Ref: GI Innovations | Image: LinkedIn